Abstracts tagged "Disease Activity"

Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
Shintaro Hirata¹, Kei Araki¹, Hiroki Kohno¹, Kazutoshi Yukawa¹, Tadahiro Tokunaga¹, Tatsuomi Kuranobu¹, Katsuhiro Oi¹, Yusuke Yoshida¹, Tomohiro Sugimoto¹, Keisuke Oda^1,2, Takaki Nojima^1,3 and Eiji Sugiyama¹, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Hiroshima Clinic, Hiroshima, Japan, ³Nojima Internal Medicine Clinic, Hiroshima, Japan
Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…
Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Peter M. ten Klooster^1,2, Laura M.M. Steunebrink³, Letty Versteeg⁴, Inmaculada de la Torre⁵, Francesco de Leonardis⁶, Walid Fakhouri⁶, Liliana Zaremba-Pechmann⁶ and Mart van de Laar^1,3, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ³Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
Abstract Number: 1643 • 2018 ACR/ARHP Annual Meeting
Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa
Ana-Maria Orbai¹, Klaus Krüger², Frank Behrens³, Uta Kiltz⁴, Benoit Guerette⁵, Lillian Mellars⁵, Michele Brunori⁵ and Jürgen Wollenhaupt⁶, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Medical Centre of Rheumatology, Munich, Germany, ³Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Celgene Corporation, Summit, NJ, ⁶Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: We examined clinical correlations between disease activity, as measured with the Clinical Disease Activity for PsA (cDAPSA) components and PsA life impact/health-related quality of…
Abstract Number: 1874 • 2018 ACR/ARHP Annual Meeting
Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort
Guillermo J. Pons-Estel^1,2, Graciela S. Alarcón³, Manuel Ugarte-Gil^4,5, Luis M. Vilá⁶, John D. Reveille⁷ and Gerald McGwin³, ¹Rheumatology, Hospital Provincial de Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Universidad Científica del Sur, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁷McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Over the last few years the importance of treating patients with SLE towards achieving either Remission or LDAS (Treat-to-Target approach) has become evident. We…
Abstract Number: 2472 • 2018 ACR/ARHP Annual Meeting
The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis
Maria Rydholm^1,2, Ingegerd Wikström^1,2, Sofia Hagel³, Lennart Jacobsson⁴ and Carl Turesson^1,2, ¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Although patients with early rheumatoid arthritis (RA) have substantially reduced grip strength compared to the general population, some improvement over time has been demonstrated…
Abstract Number: 2722 • 2018 ACR/ARHP Annual Meeting
Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results
Jens Rathmann¹, David Jayne², Goran Jönsson³, Mårten Segelmark⁴, Jan-Åke Nilsson⁵ and Aladdin Mohammad², ¹Rheumatology, Skanes University Hospital, Lund, Lund, Sweden, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Clinical Sciences, Nephrology, Lund University, Lund, Sweden, ⁵Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: To determine the incidence rates, predictors and outcome of severe infections in ANCA associated vasculitis (AAV). Methods: We conducted a population-based cohort study in…
Abstract Number: 2985 • 2018 ACR/ARHP Annual Meeting
Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
Vibeke Norvang^1,2, Gina Hetland Brinkmann^1,3, Joseph Sexton¹, Anna-Birgitte Aga¹, Siri Lillegraven¹, Till Uhlig^1,2, Tore Kvien^1,2, Maria Dahl Mjaavatten¹ and Espen A. Haavardsholm^1,2, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Dept. of Rheumatology, Østfold Hospital, Grålum, Norway
Background/Purpose: Treat-to-target (T2T) has become a key element in the management of rheumatoid arthritis (RA). Several different measures exist to define the preferred treatment target…
Abstract Number: 9L • 2017 ACR/ARHP Annual Meeting
Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
Vilija Oke¹, Iva Gunnarsson¹, Jessica M. Dorschner², Agneta Zickert¹, Timothy B. Niewold³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Colton Center for Autoimmunity, New York University, New York, NY

Background/Purpose: Serum induced IFN gene expression (IFN-score) is considered a golden standard to assess IFN activity in SLE. So far, IFN-scores have not been compared…
Abstract Number: 241 • 2017 ACR/ARHP Annual Meeting
Histological and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained By Ultrasound Guided Biopsy in Phase 1 of the Accelerating Medicines Partnership RA Network
Andrew Filer¹, Arthur M. Mandelin II², Edward F. DiCarlo³, Brendan Boyce⁴, Darren Tabechian⁵, Ralf G. Thiele⁶, Stephan Kelly⁷, Ellen M. Gravallese⁸, Diane Horowitz⁹, Kevin Wei¹⁰, Deepak Rao¹¹, Vivian P. Bykerk¹² and Jennifer H. Anolik¹³, ¹Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ²Rheumatology, Northwestern University, Chicago, IL, ³Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Medicine, University of Rochester Medical Center, Rochester, NY, ⁷Queen Mary University of London, London, United Kingdom, ⁸Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA, ⁹Division of Rheumatology, North Shore - Long Island Jewish Health System, Woodbury, NY, ¹⁰Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Spring, IN, ¹²2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹³Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: The AMP-RA network applies cutting edge technologies to the study of tissue obtained by ultrasound guided synovial biopsy from patients with rheumatoid arthritis (RA).…
Abstract Number: 713 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Zahi Touma³, Jiandong Su⁴, Nicole Anderson² and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Prolonged clinical remission is a desirable, though rare outcome in systemic lupus erythematosus (SLE). We recently showed that low disease activity (LDA) state confers…
Abstract Number: 1251 • 2017 ACR/ARHP Annual Meeting
Chinese Patient Reported Index with Rheumatoid Arthritis (CPRI-RA): Reliability, Validity and Agreement with DAS28 and HAQ
Man Han¹, Xun Gong¹, Xiao-po Tang¹, Hong-xiao Liu², Jian Liu³, Xin-chang Wang⁴, Jun-li Zhang⁵, Shi Chen⁶, Qing-chun Huang⁷, Yong-fei Fang⁸, Qing-jun Wu⁹, Dong-yi He¹⁰, Zhen-bin Li¹¹, Yue Wang¹², Hong Jiang¹³, Ming-li Gao¹⁴, Wei Liu¹⁵, Ying Liu¹⁶, Ze-guang Li¹⁷, Zhong-wen Zhao¹⁸, Cheng-wu Wang¹⁹, Wei-chao Liu²⁰, Hai-dong Wang²¹, Yu-qian Lou²², Qing-liang Meng²³, Chong-jie Ruan²⁴, Yan-ming Xie²⁵ and Quan Jiang²⁶, ¹Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Department of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ³The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Heifei, China, ⁴Rheumatology, The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou, China, ⁵Rheumatology, The Fifth Hospital of Xi’an City, Xi’an, China, ⁶Rheumatology, Peking University People's Hospital, Beijing, China, ⁷Rheumatology, Guangzhou Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China, ⁸Rheumatology, Southwest Hospital, Third Military Medical University, chongqing, China, ⁹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁰Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China, ¹¹Rheumatology, Bethune international peace hospital, Shi jiazhuang, China, ¹²Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, China, ¹³Rheumatology, The Ninth People's Hospital of Chongqing City, Chongqing, China, ¹⁴Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, ¹⁵Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, ¹⁶Rheumatology, The Affiliated Hospital of Shangdong University of Traditional Chinese Medicine, Qingdao, China, ¹⁷Rheumatology, The First Affiliated Hospital of Hei Longjiang University of Traditional Chinese Medicine, Ha Erbin, China, ¹⁸Rheumatology, The Second People's Hospital of Fujian Province, Fujian, China, ¹⁹Rheumatology, The First Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China, ²⁰Rheumatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China, ²¹Rheumatology, Gansu Provincial Hospital of Traditional Chinese Medicine, Shanxi, China, ²²Henan Rheumatism Hospital, Zhengzhou, China, ²³Rheumatology, Henan Provincial Hospital of Traditional Chinese Medicine, Zhengzhou, China, ²⁴Rheumatology and Pain Management Department, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, China, ²⁵Clinical Evaluation Center, China Academy of Chinese Medical Sciences, Beijing, China, ²⁶Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Background/Purpose: The use of patient reported outcomes(PROs) has become increasingly popular in the chronic disease management, disease monitoring and the assessment of drug efficacy. However,…
Abstract Number: 1553 • 2017 ACR/ARHP Annual Meeting
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There is a need to better characterize patients with ankylosing spondylitis (AS) who discontinue vs continue TNF inhibitor (TNFi) therapies in real-world clinical settings.…
Abstract Number: 1849 • 2017 ACR/ARHP Annual Meeting
Urinary Epidermal Growth Factor and Monocyte Chemoattractant Protein-1 As Biomarkers of Renal Involvement in ANCA-Associated Vasculitis
Catherine E. Najem¹, Wenjun Ju², Viji Nair², David Cuthbertson³, Rennie L. Rhee¹, Laura Mariani⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁵, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹, Steven R. Ytterberg¹⁴, Jeffrey Krischer¹⁵, Matthias Kretzler⁴ and Peter A. Merkel¹⁶, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Michigan, Ann Arbor, MI, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Boston University School of Medicine, Boston, MA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵University of South Florida, Tampa, FL, ¹⁶Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose :Epidermal growth factor (EGF) mediates distal tubular epithelial cell function and regeneration. Monocyte chemoattractant protein-1 (MCP-1) participates in recruitment of leukocytes to areas of…
Abstract Number: 2372 • 2017 ACR/ARHP Annual Meeting
Obesity and the Impact on Treat to Target Goals and Functional Ability in RA. Results from Two Multi-Centre UK Inception Cohorts
Elena Nikiphorou¹, Sam Norton², Patrick Kiely³ and Adam Young⁴, ¹Academic Rheumatology Department, King's College London, London, United Kingdom, ²Academic Rheumatology, King´s College London, London, United Kingdom, ³St George's Hospital, London, United Kingdom, ⁴University of Hertfordshire, Hertford, United Kingdom
Background/Purpose: The links between inflammation, obesity and joint dysfunction are well established. How these translate into clinical disease activity and functional disability in rheumatoid arthritis…
Abstract Number: 2625 • 2017 ACR/ARHP Annual Meeting
Predicting Flares in Patients with Stable Systemic Lupus Erythematosus
Jiacai Cho¹, Manjari Lahiri¹, Lay Kheng Teoh¹, Preeti Dhanasekaran^2,3, Pak Moon Peter Cheung¹ and Aisha Lateef¹, ¹Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ²National University of Singapore, singapore, Singapore, ³National University Hospital of Singapore, Singapore, Singapore
Background/Purpose: The course of systemic lupus erythematosus (SLE) varies with periods of quiescence punctuated by flares. Predicting exacerbations allows clinicians to select patients who need…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].